Skip to Content
Merck
  • Pharmacokinetics of loxoprofen and its active metabolite after dermal application of loxoprofen gel to rats.

Pharmacokinetics of loxoprofen and its active metabolite after dermal application of loxoprofen gel to rats.

Die Pharmazie (2015-05-23)
R Sawamura, M Kazui, A Kurihara, T Izumi
ABSTRACT

This study was conducted to evaluate the pharmacokinetics of loxoprofen (LX) and its active metabolite (trans-OH form) after a single dermal application of LX gel (LX-G) to rats. In the skin at the treated site, generation of the trans-OH form was detected and both LX and the trans-OH form remained at high concentrations for 24 h after dermal application. Furthermore, both LX and the trans-OH form also remained in the skeletal muscle over 24 h after the single dermal application, while they eliminated rapidly after the single oral administration. The area under the curve up to the last measurable point (AUC(0-t)) for plasma concentrations of LX or the trans-OH form after dermal application of LX-G was less than 11% of that after oral administration of LX. In addition, C(max) and AUC(0-t) increased in a saturable manner while increasing the dose. Overall, these results demonstrated that the trans-OH form was generated at the treated site with the process of dermal absorption of LX and it remained at the target site for a long period with low systemic exposure compared to oral administration.

MATERIALS
Product Number
Brand
Product Description

Supelco
Phenobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Propyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard
Supelco
Propylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Propylparaben, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Propyl 4-hydroxybenzoate, ≥99%
Sigma-Aldrich
Phenobarbital
Sigma-Aldrich
Propyl 4-hydroxybenzoate, BioXtra
Sigma-Aldrich
Propyl 4-hydroxybenzoate, tested according to Ph. Eur.